Determining the true best price of a prescription drug is one of the most complex parts of the Medicaid Drug Rebate Program. The system depends heavily on manufacturers to report accurate pricing data. When reported prices fail to reflect the true net cost of a drug, Medicaid rebates are often underpaid and False Claims Act liability can follow.
Our firm represents whistleblowers and organizations involved in pricing fraud, rebate manipulation, and healthcare fraud enforcement matters.
Best price is defined as the lowest price a manufacturer offers a covered outpatient drug to any purchaser in the United States. The reported price must reflect the actual net price after all price concessions are applied.
Certain government programs are excluded, including the Veterans Administration, Department of Defense, and Indian Health Service.
Manufacturers must also report the Average Manufacturer Price, called AMP. Both figures directly affect Medicaid rebate payments.
The system involves manufacturers, pharmacies, wholesalers, CMS, and state Medicaid agencies. The manufacturer reports AMP and best price to CMS. CMS calculates the unit rebate amount. States apply that figure to pharmacy utilization data to determine how much is owed.
The entire process depends on accurate self reporting. Incorrect data leads to underpayment and enforcement risk.
Best price manipulation is one of the most common forms of healthcare fraud. The Office of Inspector General and the Department of Justice actively investigate these cases due to the financial harm caused to Medicaid.
Manufacturers face liability when government reimbursement depends on pricing data that is incomplete or misleading.
Manufacturers often use complex contracting structures that involve rebates, bundled discounts, and indirect price adjustments. These concessions must be reflected accurately in best price reporting.
Pricing benefits that affect net cost include:
When these arrangements are not properly reflected, reported prices become artificially high and rebate payments become artificially low.
Pharmaceutical Benefit Managers receive rebates and administrative fees that often influence the real market price of drugs. When these arrangements reduce the effective price paid in the supply chain, the price reduction must be reflected in best price reporting.
Failure to do so creates significant False Claims Act exposure.
Many best price fraud cases begin with insiders who uncover pricing structures that conflict with what is reported to CMS. Common whistleblowers include pricing analysts, compliance officers, sales executives, and PBM contract managers.
The False Claims Act allows private individuals to file cases on behalf of the government and receive a share of the recovery.
We assist clients with:
Each case requires close review of pricing contracts, rebate terms, and reporting methods. Concerns involving best price reporting, AMP calculations, rebate underpayments, or concealed pricing concessions should be addressed promptly.
Contact our office to request a confidential case review.
This website is designed to provide general information only. This information is not and should not be construed to be legal advice. The transmission of the information found on this website also does not result in the formation of a lawyer-client relationship.
You should be aware that qui tam claims are subject to a Statute of Limitations. The area of limitations periods is complex. There are also first to file rules, public disclosure bars, original source issues, and varying limitations in pursuing retaliation claims. If you wish to pursue your claims, you should promptly seek the opinion of an attorney regarding the merits of your qui tam claim and the applicable statute of limitations.
Questions about the False Claims Act, Tax Fraud or the Financial Fraud Programs and whether or not you have a case? Submit our confidential form and the Law Offices of David Berg will evaluate your potential case immediately.